Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab

Journal of Neuro-Oncology

Volumn 105, Issue 1, 2011, Pages 91-101

  Ellingson, Benjamin M ^a   Cloughesy, Timothy F ^a   Lai, Albert ^a   Nghiemphu, Phioanh L ^a   Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Biomarkers; CIMPLE maps; Diffusion MRI; Glioblastoma

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN TISSUE; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RECURRENT CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; COHORT STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 82955236118     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0567-8     Document Type: Article

References (37)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Morosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvent temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. Murakami M, Jay V, Al-Shail E, Rutka JT: Brain tumors that disseminate along cerebrospinal fluid pathways and beyond (1998) In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenblum ML (eds) Brain tumor invasion: biological, clinical and therapeutic considerations. Wiley-Liss, Inc., New York, pp 111-132
3. Ellingson BM, Rand SD, Malkin MG, Prost R, Connelly JM, LaViolette PS, Bedekar DP, Schmainda KM (2010) Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise analytical solution to a glioma growth model and serial diffusion MRI. Proc Intl Soc Mag Reson Med 18:612
4. Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM (2011) Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med 65(4):1131-1143
5. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538-548
6. Rockne R, Alvord EC Jr, Rockhill JK, Swanson KR (2009) A mathematical model for brain tumor response to radiation therapy. J Math Biol 58:561-578
7. Swanson KR, Rostomily RC, Alvord EC Jr (2008) A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof or principle. Br J Cancer 98:113-119
8. Swanson KR, Alvord EC Jr, Murray JD (2002) Quantifying efficacy of chemotherapy of brain tumors with homogeneous and heterogeneous drug delivery. Acta Biotheor 50:223-237 (Pubitemid 36325757)
9. Reese TG, Heid O, Weisskoff RM, Wedeen VJ (2003) Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med 49:177-182 (Pubitemid 36042349)
10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
11. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26: 2466-2474
12. Farlow SJ (1993) Partial differential equations for scientists and engineers. Wiley, New York
13. Cox RW, Jesmanowicz A (1999) Real-time 3D image registration for functional MRI. Magn Reson Med 42:1014-1018
14. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217-1222
15. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259 (Pubitemid 46424067)
16. Friedman AH, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
17. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum ML, Reuter VE, DeAngelis LM, Lassman AB (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200-1206
18. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787
19. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy TF, Mischel PS, Lai A, Nghiemphu PL, Rahmanuddin S, Goldin J (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182-189
20. Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM (2011) Volumetric analysis of functional diffusion maps (fDMs) is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 102(1):95-103
21. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A ''vascular normalization index'' as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296-5300
22. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714-4721 (Pubitemid 350086472)
23. Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, Chandler JP, Levy R, Getch C, Carroll TJ (2010) Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology 255: 622-628
24. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB (1987) Stereotactic histological correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62: 450-459 (Pubitemid 17084816)
25. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ (1987) Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:865-874 (Pubitemid 17085708)
26. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444
27. Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5:610-620
28. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233-242
29. Swanson KR, Alvord EC Jr, Murray JD (2000) A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif 33:317-329
30. Harpold HLP, Alvord EC Jr, Swanson KR (2007) The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66:1-9 (Pubitemid 46066783)
31. Lyng H, Haraldseth O, Rofstad EK (2000) Measurements of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828-836 (Pubitemid 30387603)
32. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okudo T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53-60 (Pubitemid 29068231)
33. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD (2000) Diffusion magnetic resonance imaging: an early surrogate marker for therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029-2036 (Pubitemid 32045900)
34. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, Makino K, Nakamura H, Ikushima I, Yamura M, Kochi M, Kuratsu JI, Yamashita Y (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27: 1419-1425 (Pubitemid 44260120)
35. Gauvain KM, McKinstry RC, Mukherjee P, Perry A, Neil JJ, Kaufman BA, Hayashi RJ (2001) Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 177:449-454 (Pubitemid 32660511)
36. Kinoshita M, Hashimoto N, Goto T, Kagawa N, Kishima H, Izumoto S, Tanaka H, Fujita N, Yoshimine T (2008) Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant tumors. Neuroimage 43:29-35
37. Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, Wakasa K, Yamada R (2001) The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 22:1081-1088 (Pubitemid 32587420)